Sten Nilsson

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Medicine, Nuclear Medicine, Radiation Oncology +17

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

Sten Nilsson, Lars Franzén, Christopher Parker et al. · The Lancet Oncology · 2007 · 493 citations

Medicine, Oncology, Radiation Oncology +15

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 491 citations

Medicine, Oncology, Pharmacology +17

First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

Sten Nilsson, Roy H. Larsen, Sophie D. Fosså et al. · Clinical Cancer Research · 2005 · 433 citations

Medicine, Oncology, Radiation Oncology +17

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

Peter Hoskin, Oliver Sartor, Joe M. O’Sullivan et al. · The Lancet Oncology · 2014 · 407 citations

Medicine, Oncology, Pharmacology +17